Vanderbilt-Ingram Cancer Center: Myelodysplastic Syndromes trials

The registry lists 10 Myelodysplastic Syndromes studies with Vanderbilt-Ingram Cancer Center as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 3Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaRecruitingNCT06399640Phase 1
• Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsCompletedNCT03238248Phase 2Results posted
• Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid LeukemiaCompletedNCT02658487Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaWithdrawnNCT04013880Phase 1/2
• Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell TransplantCompletedNCT00900406
• T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT00651716
• Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable